H.R. 5057 — Introduced in House

I 116th CONGRESS 1st Session H. R. 5057 IN THE HOUSE OF REPRESENTATIVES November 12, 2019Mr. Tonko (for himself and Mr. McKinley) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To clarify the treatment of pass-through status under the Medicare outpatient payment system for certain drugs. 1. Short title This Act may be cited as the Pass-Through Technical Corrections Act. 2. Clarification of pass-through status under Medicare OPPS for certain drugs Notwithstanding section 1301 of the Consolidated Appropriations Act of 2018 (Public Law 115–141), in the case of a radiopharmaceutical drug for which pass-through status was provided pursuant to section 1833(t)(6) of the Social Security Act (42 U.S.C. 1395l(t)(6)) and whose period of pass-through status initially expired on either December 31, 2017, or December 31, 2018, if such radiopharmaceutical drug is indicated for positron emission tomography beta amyloid imaging covered under a coverage evidence development determination under section 1862(a)(1)(E) of the Social Security Act (42 U.S.C. 1395y(a)(1)(E)), then such pass-through status shall be extended until such date that the coverage with evidence development review is determined by the Centers for Medicare & Medicaid Services to be completed.